Journal of Clinical Oncology PNOC001: Phase II Study of Everolimus For Recurrent or Progressive Low-Grade Gliomas in Children


The PNOC001 phase II single-arm trial sought to estimate progression-free survival (PFS) associated with everolimus therapy for progressive/recurrent pediatric low-grade glioma (pLGG) on the basis of phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway activation as measured by phosphorylated-ribosomal protein S6 and to identify prognostic and predictive biomarkers.


Previous
Previous

Neuro-Oncology Rational combination platform trial design for children and young adults with diffuse midline glioma

Next
Next

American Association for Cancer Research Journal ONC201 in Combination with Paxalisib for the Treatment of H3K27-Altered Diffuse Midline Glioma